Epigenetic Biomarkers and Diagnostics

<p>Preface<br>José Luis García-Giménez</p> <p>1.  Epigenetic Biomarkers: New findings, perspectives, and future directions in diagnostics<br>José Luis García-Giménez, Toshikazu Ushijima, and Trygve O. Tollefsbol</p> <p>2. The importance of Biobanks in epigenetic studies<br>Lorena Peiró-Chova, Olga Bahamonde Ponce, Carolina Abril-Tormo, Jacobo Martínez-Santamaría, José Antonio López-Guerrero and Peter H.J. Riegman</p> <p>3. Epigenetic Mechanisms as Key Regulators in Disease. Clinical Implications<br>Abdelhalim Boukaba, José Luis García-Giménez</p> <p>4. The evolution of new technologies and methods in clinical epigenetics research<br>Tandy L. Dolin Petrov and Nicole C. Riddle</p> <p>5. Biomarkers and methodologies for monitoring epigenetic drug effects in cancer<br>Marianne B. Treppendahl, Lasse Sommer Kristensen and Kirsten Grønbæk</p> <p>6. Genome-wide techniques for the study of clinical epigenetic biomarkers<br>Eneda Toska and F Javier Carmona Sanz</p> <p>7. Sequenom MassARRAY technology for the analysis of DNA methylation. Clinical applications<br>Enrique J. Buso and Marisa Iborra</p> <p>8. The role of Methylation-specific PCR and associated techniques in clinical diagnostics<br>Fang Zhao and Bharati Bapat</p> <p>9. Pyrosequencing and its application in epigenetic clinical diagnostics<br>Ana-Maria Florea</p> <p>10. Mass spectrometry for the identification of post-translational modifications in histones and its application in clinical epigenetics<br>Roberta Noberini, Alessandro Cuomo and Tiziana Bonaldi</p> <p>11. High-throughput analysis of non-coding RNAs: implications in clinical epigenetics<br>Valerio Costa, Maria R Matarazzo, Miriam Gagliardi, Roberta Esposito, Alfredo Ciccodicola</p> <p>12. Circulating non-coding RNAs as clinical biomarkers<br>Francesco Russo, Flavia Scoyni, Alessandro Fatica, Marco Pellegrini, Alfredo Ferro, Alfredo Pulvirenti and Rosalba Giugno</p> <p>13. DNA methylation biomarkers in lung cancer<br>Juan Sandoval and Paula Lopez Serra</p> <p>14. DNA methylation alterations as biomarkers for Prostate Cancer<br>João Ramalho-Carvalho, Rui Henrique, Carmen Jerónimo</p> <p>15. DNA methylation in breast cancer<br>Raimundo Cervera, Alberto Ramos, Ana Lluch and Joan Climent</p> <p>16. DNA methylation in obesity and associated diseases<br>Ana B Crujeiras and Angel Díaz-Lagares</p> <p>17. DNA Methylation Biomarkers in Asthma and Allergy<br>Avery DeVries and Donata Vercelli</p> <p>18. DNA Methylation in Pregnancy Complications<br>Deepali Sundrani, Vinita Khot and Sadhana Joshi</p> <p>19. Epigenetics in Infectious Diseases<br>Genevieve Syn, Jenefer M. Blackwell and Sarra E. Jamieson</p> <p>20. DNA Methylation in Neurodegenerative Diseases<br>Sahar Al-Mahdawi, Sara Anjomani Virmouni and Mark A. Pook</p> <p>21. The histone code and disease: post-translational modifications as potential prognostic factors for clinical diagnosis<br>Nicolas G. Simonet, George Rasti and Alejandro Vaquero</p> <p>22. Histone Post-Translational Modifications and Chromatin Remodelers in Prostate Cancer<br>Filipa Quintela Vieira, Diogo Almeida-Rios, Inês Graça, Rui Henrique and Carmen Jerónimo</p> <p>23. Histone post-translational modifications in breast cancer and their use in clinical diagnosis and prognosis<br>Luca Magnani, Annita Louloupi and Wilbert Zwart</p> <p>24. Histone variants and post-translational modifications in spermatogenesis and infertility<br>Juan Ausio, Yinan Zhang and Toyotaka Ishibashi</p> <p>25. Circulating histones and nucleosomes as biomarkers in sepsis and septic shock<br>José Luis García Giménez, Carlos Romá Mateo, Marta Seco Cervera, José Santiago Ibañez Cabellos and Federico V. Pallardó</p> <p>26. Chromatin landscape and epigenetic signatures in neurological disorders: emerging perspectives for biological and clinical research<br>Pamela Milani and Ernest Fraenkel</p> <p>27. MicroRNAs deregulation in lung cancer and their use as clinical tools<br>Paula Lopez-Serra and Juan Sandoval</p> <p>28. Circulating Nucleic Acids as Prostate Cancer Biomarkers<br>Claire E. Fletcher, Ailsa Sita-Lumsden, Akifumi Shibakawa and Charlotte L. Bevan</p> <p>29. microRNAs in breast cancer and their value as biomarkers<br>Olafur Andri Stefansson</p> <p>30. microRNAs in bone and soft tissue sarcomas and their value as biomarkers<br>Tomohiro Fujiwara, Yu Fujita, Yutaka Nezu, Akira Kawai, Toshifumi Ozaki, Takahiro Ochiya</p> <p>31. miRNAs in the pathophysiology of diabetes and their value as biomarkers<br>Eoin Brennan, Aaron McClelland, Shinji Hagiwara, Catherine Godson and Phillip Kantharidis<br></p>